$200MSeries A, 9 January 2026
Launched with $200M Series A to advance Phase 2 COPD drug AN01 in-licensed from Haisco.
- Amount
- $200M
- Stage
- Series A
- Announced
- 9 January 2026
- Lead
- Frazier Life Sciences
- Other investors
- OrbiMed, Goldman Sachs Alternatives Life Sciences, SR One, Longitude Capital, Enavate Sciences
- Use of funds
- Launched with $200M Series A to advance Phase 2 COPD drug AN01 in-licensed from Haisco.
- Checked
- Announced by the company
- Sources
- AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For CO businesswire.com
AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For CO pulse2.com